BeyondSpring (BYSI) Fundamentals 2026 — Revenue Analysis | SniperIQ
BeyondSpring (BYSI) is a US-listed Healthcare company in Biotechnology with a market capitalization of $49M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BeyondSpring's market cap?
BeyondSpring (BYSI) has a market capitalization of approximately $49M, trading at
How profitable is BeyondSpring?
BeyondSpring runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does BeyondSpring pay a dividend?
BeyondSpring does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is BeyondSpring financially healthy?
BeyondSpring carries a debt-to-equity ratio of -0.01x and a current ratio of 1.09x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BeyondSpring a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BeyondSpring (BYSI) the key facts are: market cap $49M, 52-week range 1.16-2.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track BeyondSpring's full fundamentals live
Get BeyondSpring's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.